Methods: We conducted a transversal, descriptive study. The Diagnostic Microbiology Lab collected M. abscessusclinical isolates during the 2014 calendar year. The MICs for tedizolid and linezolid were determined using Research-use-only broth microdilution panels with Tedizolid and linezolid (0.06-8 µg/mL) from Thermo Scientific Sensititre according to CLSI M24-A2.
Results: Of 38 isolates tested, 4 were excluded due to either contamination on the purity plate, no growth on the MIC plate, or both. When tedizolid and linezolid MICs were compared, 47% of the isolates were 4-fold more susceptible to tedizolid and 29% were at least 8-fold more susceptible. Fourteen isolates had tedizolid MICs ≤1 µg/mL, 13 had MICs of 2 µg/mL and 4 had MICs of 4 µg/mL. We noted 10 isolates were non-susceptible to linezolid (MIC>8 µg/mL), 7 of these had tedizolid MICs ranging from 2 to 4 µg/mL.
Conclusion: Our in vitro data suggest tedizolid is likely to be an effective option for treating M. abscessus infections.
L. Steed, None